Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 2 N=10 Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Alpha 1 Antitrypsin Deficiency
Primary: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid — 14.3; 8.1; 10.3; 379.9 pg/ml — p=<0.05
Phase 3 N=105 Analgesic Effect of Peripheral Dexmedetomidine
Third Molar Extraction
Primary: Pain Score at Rest — 165.5; 218.2; 233.8 score on a scale×hr
Phase 1 N=9 Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency
Alpha 1-Antitrypsin Deficiency
Primary: Adverse Events Possibly, Probably or Definitely Related to Study Drug — 2; 2; 3; 2 participants
Phase 3 N=24 Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Alpha 1-Antitrypsin Deficiency
Primary: Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7 — 155.9; 152.4 mg*h/mL
Phase 3 N=38 The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion. — 38; 26; 17; 5…
Phase 2 N=16 Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b — -83.07; -79.84; -81.58; -12.91 percent change
Phase 2 N=15 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Phase 2 N=30 Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
Emphysema · Alpha 1-antitrypsin Deficiency (AATD)
Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 18 participants
Phase 3 N=4 Therapy to Elevate CD4 Counts in HIV-1 Disease
HIV Disease
Primary: CD4/CD8 Ratio — 0.44 Ratio
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 2 N=9 Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency
Primary: Frequency of Grade 3 or 4 Adverse Events — 0; 0; 1 participants
Phase 2 N=4 Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4 Participants